Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 29.88% is 33% above its 3-year average of 22.42%, near the high end of its 3-year range (5.40%–36.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.46% above its 12-month average of 26.10%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 29.88%.
RETURN ON EQUITY (ROE)
29.88%
RETURN ON EQUITY (ROE) AVG TTM
26.10%
RETURN ON EQUITY (ROE) AVG 3Y
22.42%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.46%
CURRENT VS 3Y AVG
+33.22%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+129.63%
vs the sector median at left
Solventum Corporation
Market Cap
$15.14B
Return on Equity (ROE)
29.88%
TTM Avg
26.10%
3Y Avg
22.42%
5Y Avg
N/A
Market Cap
$14.11B
Return on Equity (ROE)
46.68%
TTM Avg
29.72%
3Y Avg
22.87%
5Y Avg
17.28%
Market Cap
$16.40B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$13.87B
Return on Equity (ROE)
3.29%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$13.40B
Return on Equity (ROE)
-8.40%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
Market Cap
$12.52B
Return on Equity (ROE)
10.49%
TTM Avg
6.83%
3Y Avg
5.29%
5Y Avg
3.21%
Market Cap
$12.30B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$18.09B
Return on Equity (ROE)
6.39%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
Market Cap
$12.07B
Return on Equity (ROE)
23.91%
TTM Avg
22.63%
3Y Avg
21.83%
5Y Avg
21.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $15.14B | 29.88% | 26.10% | 22.42% | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.11B | 46.68% | 29.72% | 22.87% | 17.28% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 113.29% | 73.63% | 65.34% | 49.74% |
| Revvity, Inc. (RVTY)vs › | $13.87B | 3.29% | 3.59% | 3.35% | 7.68% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.40B | -8.40% | -2.13% | 6.32% | 9.65% |
| Penumbra, Inc. (PEN)vs › | $12.52B | 10.49% | 6.83% | 5.29% | 3.21% |
| Baxter International Inc. (BAX)vs › | $12.30B | -17.13% | -12.46% | -8.76% | -1.37% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 6.39% | 6.40% | 5.73% | 4.16% |
| Encompass Health Corporation (EHC)vs › | $12.07B | 23.91% | 22.63% | 21.83% | 21.13% |
| DaVita Inc. (DVA)vs › | $11.66B | N/A | 329.18% | 200.63% | 164.66% |
ROE
29.9%
ROA
10.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 29.88% |
| 2026-03-31 | 28.82% |
| 2025-12-31 | 30.82% |
| 2025-09-30 | 30.57% |
| 2025-06-30 | 10.43% |
| 2025-03-31 | 11.62% |
| 2024-12-31 | 16.19% |
| 2024-09-30 | 22.56% |
| 2024-06-30 | 36.90% |
| 2024-03-31 | 33.50% |
| 2023-12-31 | 11.54% |
| 2023-09-30 | 23.32% |
| 2023-06-30 | 5.40% |
